Eli Lilly’s Alzheimer’s Drug Donanemab Faces Delay in Approval for FDA Review
Eli Lilly's quest to bring donanemab, a promising Alzheimer's treatment, to market has encountered a roadblock. The U.S. Food and ...
Eli Lilly's quest to bring donanemab, a promising Alzheimer's treatment, to market has encountered a roadblock. The U.S. Food and ...